



Long Island Bioscience Hub Announces Funded Projects

Accelerating the development of biomedical technologies

STONY BROOK, N.Y. – May 5, 2016 - The [Center for Biotechnology](#) at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced today the recipients of the second round of funded projects under the Hub's technology development and commercialization initiative. Funding for ten projects totaling \$600,000 was awarded to applicants from the Hub's partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute at Northwell Health Systems.

The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards (\$50,000) are designed to rapidly test the feasibility of new ideas in a "fail-fast-or-proceed" format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards (\$100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.

A wide range of disciplines are represented in the project awards this cycle including biomedical engineering, chemistry, biochemistry, psychiatry, molecular genetics and microbiology, and pathology and dermatology. Eight Feasibility awards and two Proof of Concepts awards have been funded this cycle. The recipients of this round of awards are:

Feasibility awards

Therapeutic for Clostridium difficile antibiotic-associated diarrheal disease – Dr. James Bliska

Device for rapid, simple and highly parallel single-cell processing – Dr. Eric Brouzes

Developing a small molecule drug to treat systemic C. albicans infections – Dr. Nick Carpino

Next generation hedgehog inhibitor for invasive basal cell carcinoma – Dr. Jiang Chen

A Novel Strategy for Recombinant AAV Vector Production for Gene Therapy – Dr. Patrick Hearing

A tandem-integration-based multi-barcode method for high-throughput combinatorial screening – Dr. Sasha Levy

Novel CAIX Targeted Combination Inhibitor/PET tracer to treat patients with solid tumors – Dr. Peter Smith-Jones

Substrate-Assisted Tethered Inhibitors of LigA to Treat MDR Gonorrhea – Dr. Peter Tonge

Proof of Concept awards

fMRI Dynamic Phantom for Improved Detection of Resting-State Brain Networks - Dr. Lilianne Mujica-Parodi

Development of SMASH technology as a next-gen sequencing diagnostic for congenital heart disease - Dr. Michael Ronemus

“The announcement of this second cycle of awards from the Long Island Bioscience Hub under the NIH-REACH program is exemplary of the increasing commercially relevant research taking place in the region” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Coupled with the recent expansion of the Hub to include the Feinstein Institute and the announcement of our third “request for proposals,” the LIBH is steadily working toward its goal of accelerating the translation of these technologies from the bench to the bed side.”

The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

Contact:

Diane Fabel

Director of Operations

diane.fabel@stonybrook.edu

631-632-8521

###

About the Long Island Bioscience Hub

The Long Island Bioscience Hub, a National Institutes of Health-designated Research, Evaluation, and Commercialization Hub, represents a partnership between the Center for Biotechnology, Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory and the Feinstein Institute for Medical Research to commercialize biomedical innovations emerging from the partner institutions. In addition to the support provided by NIH and the partner institutions, the Long Island Bioscience Hub is supported by Empire State Development and The Research Foundation for SUNY. Together, the Center for Biotechnology and Long Island Bioscience Hub represent a significant opportunity to expand technology commercialization and company formation in the region and throughout New York State.

About the Center for Biotechnology at Stony Brook University

Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology. The CFB’s programs specifically target the development and commercialization of biomedical based technologies and critical components and staff of the LIBH will be supported by the CFB.